Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?
Kuemmel S, Jackisch C, Mueller V, Schneeweiss A, Klawitter S, Lux MP (2017)
Publication Type: Conference contribution
Publication year: 2017
Journal
Book Volume: 28
Involved external institutions
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Roche Deutschland Holding GmbH
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Germany (DE)
Roche Deutschland Holding GmbH
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
How to cite
APA:
Kuemmel, S., Jackisch, C., Mueller, V., Schneeweiss, A., Klawitter, S., & Lux, M.P. (2017). Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?.
MLA:
Kuemmel, S., et al. "Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?" 2017.
BibTeX: Download